CZ132199A3 - Heteroarylsukcinamidy a jejich použití jako inhibitory metalloproteinázy - Google Patents

Heteroarylsukcinamidy a jejich použití jako inhibitory metalloproteinázy

Info

Publication number
CZ132199A3
CZ132199A3 CZ991321A CZ132199A CZ132199A3 CZ 132199 A3 CZ132199 A3 CZ 132199A3 CZ 991321 A CZ991321 A CZ 991321A CZ 132199 A CZ132199 A CZ 132199A CZ 132199 A3 CZ132199 A3 CZ 132199A3
Authority
CZ
Czechia
Prior art keywords
succinamides
heteroaryl
metalloproteinase inhibitors
metalloproteinase
inhibitors
Prior art date
Application number
CZ991321A
Other languages
English (en)
Inventor
Steven L. Bender
Arlindo L. Castelhano
Wesley K. M. Chong
Melwyn A. Abreo
Roland J. Billedeau
Jian Jeffrey Chen
Judith G. Deal
Original Assignee
Agouron Pharmaceuticals, Inc.
Syntex (U. S. A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Syntex (U. S. A.) Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of CZ132199A3 publication Critical patent/CZ132199A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ991321A 1996-10-24 1997-10-06 Heteroarylsukcinamidy a jejich použití jako inhibitory metalloproteinázy CZ132199A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2911596P 1996-10-24 1996-10-24
US08/823,962 US6008243A (en) 1996-10-24 1997-03-25 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

Publications (1)

Publication Number Publication Date
CZ132199A3 true CZ132199A3 (cs) 1999-09-15

Family

ID=26704557

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ991321A CZ132199A3 (cs) 1996-10-24 1997-10-06 Heteroarylsukcinamidy a jejich použití jako inhibitory metalloproteinázy

Country Status (25)

Country Link
US (1) US6008243A (cs)
EP (1) EP0937042A1 (cs)
JP (1) JP2000511201A (cs)
KR (1) KR20000052779A (cs)
CN (1) CN1233237A (cs)
AP (1) AP1360A (cs)
AR (1) AR009124A1 (cs)
AU (1) AU735194C (cs)
BG (1) BG64506B1 (cs)
BR (1) BR9713278A (cs)
CA (1) CA2267879C (cs)
CZ (1) CZ132199A3 (cs)
EA (1) EA003127B1 (cs)
EE (1) EE9900171A (cs)
GE (1) GEP20012578B (cs)
IL (1) IL128914A (cs)
IS (1) IS5000A (cs)
NO (1) NO313281B1 (cs)
NZ (1) NZ334886A (cs)
OA (1) OA11035A (cs)
PL (1) PL332947A1 (cs)
SK (1) SK48499A3 (cs)
TR (2) TR200402157T2 (cs)
WO (1) WO1998017643A1 (cs)
YU (1) YU20199A (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576664B1 (en) * 1997-08-18 2003-06-10 Bristol-Myers Squibb Pharma Company Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
JP2002508323A (ja) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
WO1999041232A1 (en) * 1998-02-13 1999-08-19 British Biotech Pharmaceuticals Limited Cytostatic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
BR0207209A (pt) * 2001-02-14 2004-01-27 Warner Lambert Co Inibidores de metaloproteinase de matriz de pirimidina
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
JP2006502991A (ja) * 2002-07-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物
MXPA05000476A (es) * 2002-07-17 2005-03-23 Warner Lambert Co Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib.
MXPA05000722A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico carboxilico de la metaloproteinasa-13 de la matriz con un inhibidor selectivo de la ciclooxigenasa-2 que no es celecoxib o valdecoxib.
EP1531904A1 (en) * 2002-07-17 2005-05-25 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
JP2006504665A (ja) * 2002-08-13 2006-02-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004014908A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014378A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MXPA05001783A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003249540A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
MXPA05001785A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249532A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US8691835B2 (en) * 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US20110009435A1 (en) * 2007-06-05 2011-01-13 Pfizer, Inc. Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20141637A1 (es) * 2011-04-28 2014-11-20 Japan Tobacco Inc Compuesto de amida y aplicacion farmaceutica para el mismo
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106749128A (zh) * 2017-01-13 2017-05-31 滕州市悟通香料有限责任公司 一种制备2‑甲基‑3‑巯基呋喃的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
CA2073513A1 (en) * 1990-12-03 1992-06-04 John Robert Porter Peptidyl derivatives
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
WO1994012169A1 (en) * 1992-11-25 1994-06-09 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
DE69419473T2 (de) * 1993-04-27 2000-03-16 Celltech Therapeutics Ltd. Peptidylderivate als inhibitoren von metalloproteinase
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
JPH09501430A (ja) * 1993-08-05 1997-02-10 シンテックス（ユー・エス・エイ）・インコーポレイテッド マトリックスメタロプロテアーゼ阻害因子
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
ATE181055T1 (de) * 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DK0757984T3 (da) * 1995-08-08 2003-03-03 Ono Pharmaceutical Co Hydroxamsyrederivater, der kan anvendes til inhibering af gelatinase
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
PT861236E (pt) * 1995-11-13 2002-07-31 Hoechst Ag Acidos alfa-iminohidoxamicos e carboxilicos n-substituidos ciclicos e heterociclicos
NZ321293A (en) * 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
TR199800990T2 (xx) * 1995-12-08 1998-07-21 Agouron Pharmaceuticals, Inc. Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
JP2000502343A (ja) * 1995-12-22 2000-02-29 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼのインヒビターとしての芳香族ケト酸およびその誘導体
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
ES2284180T3 (es) * 1996-01-23 2007-11-01 SHIONOGI & CO., LTD. Derivados de aminoacidos sulfonados e inhibidores de metaloproteinasas que contienen los mismos.
BR9711223A (pt) * 1996-08-23 1999-08-17 Pfizer Derivados de cido arilsulfonilamino-hidrox mico
ATE226193T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Substituierte zyklische amine als metalloproteaseinhibitoren
AU731319B2 (en) * 1996-08-28 2001-03-29 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
EA199900366A1 (ru) 1999-10-28
NZ334886A (en) 2000-11-24
TR200402157T2 (tr) 2005-02-21
NO991922L (no) 1999-04-22
AP9901536A0 (en) 1999-06-30
IL128914A (en) 2003-04-10
EE9900171A (et) 1999-12-15
AU4806097A (en) 1998-05-15
CN1233237A (zh) 1999-10-27
SK48499A3 (en) 2000-04-10
AU735194C (en) 2002-08-08
JP2000511201A (ja) 2000-08-29
YU20199A (sh) 2001-09-28
IS5000A (is) 1999-03-12
OA11035A (en) 2002-03-06
PL332947A1 (en) 1999-10-25
AR009124A1 (es) 2000-03-08
AU735194B2 (en) 2001-07-05
CA2267879A1 (en) 1998-04-30
TR199900874T2 (xx) 1999-07-21
KR20000052779A (ko) 2000-08-25
IL128914A0 (en) 2000-02-17
EP0937042A1 (en) 1999-08-25
AP1360A (en) 2005-01-05
NO991922D0 (no) 1999-04-22
US6008243A (en) 1999-12-28
BG64506B1 (bg) 2005-05-31
WO1998017643A1 (en) 1998-04-30
BG103415A (en) 2000-07-31
EA003127B1 (ru) 2003-02-27
NO313281B1 (no) 2002-09-09
GEP20012578B (en) 2001-11-26
BR9713278A (pt) 1999-11-03
CA2267879C (en) 2006-03-14

Similar Documents

Publication Publication Date Title
IL128914A0 (en) Heteroaryl succinamides and their use as metalloproteinase inhibitors
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
PL340560A1 (en) Heteroaryl aminoguanidines and alkoxyguanidines and their application as protease inhibitors
IL128514A0 (en) Novel acetamide derivatives and protease inhibitors
IL128664A0 (en) Heterocyclic metalloprotease inhibitors
IL127885A0 (en) Amidino derivatives and their use as thrombin inhibitors
ZA9710646B (en) Aminoguanidines and alkoxyguanidines as protease inhibitors
EP0927035A4 (en) THROMBIN INHIBITORS
PL328307A1 (en) Serinic protease inhibitors
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
HUP0001826A3 (en) Thrombin inhibitors
PL331803A1 (en) Bidonoric metaloprotease inhibitors
PL328875A1 (en) Serinic protease inhibitors
PL328223A1 (en) Aspartil protease inhibitors
HUP9904165A3 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
GB9613718D0 (en) Thrombin inhibitors
GB9624817D0 (en) Metalloproteinase inhibitors
HUP9903376A3 (en) Heteroaryl succinamides and their use as metalloproteinase inhibitors
GB2299334B (en) Metalloproteinase inhibitors
GB9626672D0 (en) Metalloproteinase inhibitors
GB9610985D0 (en) Metalloproteinase inhibitors
GB9625154D0 (en) Metalloproteinase inhibitors
GB9625871D0 (en) Metalloproteinase inhibitors
ZA979406B (en) Metalloproteinase inhibitors pharmaceutical compositions containing them and their use
GB9623742D0 (en) Inhibitors

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic